//img.uscri.be/pth/80efcc78c5414bf43d754e56a965009ace474a0c
Cet ouvrage fait partie de la bibliothèque YouScribe
Obtenez un accès à la bibliothèque pour le lire en ligne
En savoir plus

New Applications in Drug Discovery Platforms to Fuel Advance of Stem Cells, Says Frost & Sullivan

3 pages
New Applications in Drug Discovery Platforms to Fuel Advance of Stem Cells, Says Frost & Sullivan PR Newswire LONDON, June 13, 2012 - Ethical, Clinical and Commercial Issues to be Navigated before Full Potential of Stem Cell Therapies can be Unleashed LONDON, June 13, 2012 /PRNewswire/ -- Stem cells offer exciting potential in regenerative medicine, and are likely to be widely used by mid-2017. Pharmaceutical, biotech and medical device companies are showing increased interest in stem cell research. New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the Stem Cell Markets-Unlocking the New Era in Therapeutics, finds that the market will be driven by stem cell applications in drug discovery platforms and by successful academia –commercial company partnership models. "The high attrition rates of potential drug candidates has piqued the interest of pharmaceutical and biotech industries in stem cell use during the drug discovery phase," notes Frost & Sullivan Consulting Analyst Vinod Jyothikumar. "Previously, animal cell lines, tumours, or genetic transformation have been the traditional platform for testing drug candidates; however, these 'abnormal' cells have significantly contributed to a lack of translation into clinical studies." Many academic institutes and research centres are collaborating with biotechnology and pharmaceutical companies in stem cell research. This will provide impetus to the emergence of novel cell-based therapies.
Voir plus Voir moins
New Applications in Drug Discovery Platforms
to Fuel Advance of Stem Cells, Says Frost &
Sullivan
PR Newswire
LONDON, June 13, 2012
- Ethical, Clinical and Commercial Issues to be Navigated before Full
Potential of Stem Cell Therapies can be Unleashed
LONDON
,
June 13, 2012
/PRNewswire/ -- Stem cells offer exciting potential in
regenerative medicine, and are likely to be widely used by mid-2017.
Pharmaceutical, biotech and medical device companies are showing increased
interest in stem cell research.
New analysis from Frost & Sullivan (http://www.pharma.frost.com),
Analysis of
the Stem Cell Markets-Unlocking the New Era in Therapeutics
, finds
that the market will be driven by stem cell applications in drug discovery
platforms and by successful academia –commercial company partnership
models.
"The high attrition rates of potential drug candidates has piqued the interest of
pharmaceutical and biotech industries in stem cell use during the drug
discovery phase," notes Frost & Sullivan Consulting Analyst Vinod Jyothikumar.
"Previously, animal cell lines, tumours, or genetic transformation have been the
traditional platform for testing drug candidates; however, these 'abnormal' cells
have significantly contributed to a lack of translation into clinical studies."
Many academic institutes and research centres are collaborating with
biotechnology and pharmaceutical companies in stem cell research. This will
provide impetus to the emergence of novel cell-based therapies.
Key challenges to market development relate to reimbursement, ethics and the
complexity of clinical trials.
Securing reimbursement for stem cell therapeutic products is expected to be
critical for commercial success. However, stem cell therapies are likely to be
expensive. Insurers, therefore, may be unwilling to pay for the treatment. At
the same time, patients are unlikely to be able to afford these treatments.
"The use of embryonic stem cells raises a host of thorny ethical, legal, and
social issues," adds Jyothikumar. "As a result, market prices for various
products may be affected."
Moreover, many research institutes are adopting policies promoting the ethical
use of human embryonic tissues. Such policies are hindering the overall
research process for several companies working in collaboration with these
institutes.
"In addition to apprehensions about how many products will actually make it
through human-based clinical trials, companies are also worried about which
financial model can be applied to stem cell therapies," cautions Jyothikumar.
"Possibly low return on investment (ROI) is also resulting in pharmaceutical
companies adopting a cautious approach to stem cell therapeutics."
To push through policy or regulatory reforms, the technology platform and
geographical location of stem cell companies should complement the terms